Source link : https://www.newshealth.biz/health-news/neoadjuvant-strategy-establishes-standard-of-care-for-resectable-stage-iii-melanoma/
CHICAGO — Combination neoadjuvant immunotherapy for resectable melanoma reduced recurrence and other clinical events by two-thirds versus adjuvant therapy, a randomized trial showed. Patients treated with nivolumab (Opdivo) and ipilimumab (Yervoy) and response-guided adjuvant nivolumab had an overall event rate of 13% versus 34% with adjuvant nivolumab. The difference translated into a 68% improvement in […]
Author : News Health
Publish date : 2024-06-04 21:25:04
Copyright for syndicated content belongs to the linked Source.
Categories